Page 222 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 12 Cancer Chemotherapy 201

91. Tarirai C, Viljoen AM, Hamman JH: Herb-drug pharmacokinetic 112. Rassnick KM, Bailey DB, Malone EK, et al.: Comparison between
interactions reviewed, Expert Opin Drug Metab Toxicol 6:1515– l-CHOP and an l-CHOP protocol with interposed treatments of
1538, 2010. CCNU and MOPP (l-CHOP-CCNU-MOPP) for lymphoma in
VetBooks.ir 92. Mealey KL: Therapeutic implications of the mdr-1 gene, J Vet Phar- 113. Brodsky EM, Maudlin GN, Lachowicz JL, et al.: Asparaginase
dogs, Vet Comp Oncol 8:243–253, 2010.
macol Ther 27:257–264, 2004.
93. Legha SS, Benjamin RS, Mackay B, et al.: Reduction of doxorubi-
cin cardiotoxicity by prolonged continuous intravenous infusion, and MOPP treatment of dogs with lymphoma, J Vet Intern Med
23:578–584, 2009.
Ann Intern Med 96:133–139, 1982. 114. Martin OA, Price J: Mechlorethamine, vincristine, melphalan and
94. Berrak SG, Ewer MS, Jaffe N, et al.: Doxorubicin cardiotoxicity in prednisolone rescue chemotherapy protocol for resistant feline lym-
children: reduced incidence of cardiac dysfunction associated with phoma, J Feline Med Surg1098612X17735989, 2017.
continuous-infusion schedules, Oncol Rep 8:611–614, 2001. 115. Tew KD, Colvin OM, Chabner BA: Alkylating agents. In Chab-
95. Preisler HD, Gessner T, Azarnia N, et al.: Relationship between ner BA, Longo DL, editors: Cancer chemotherapy & biotherapy:
plasma adriamycin levels and the outcome of remission induction Principles and practice, Philadelphia, 2001, Lippincott Williams &
therapy for acute nonlymphocytic leukemia, Cancer Chemother Wilkins, pp 373–414.
Pharmacol 12:125–130, 1984. 116. Fernandez R, Chon E: Comparison of two melphalan protocols
96. Piscitelli SC, Rodvold KA, Rushing DA, et al.: Pharmacokinetics and evaluation of outcome and prognostic factors in multiple
and pharmacodynamics of doxorubicin in patients with small cell myeloma in dogs, J Vet Intern Med 32:1060–1069, 2018.
lung cancer, Clin Pharmacol Ther 53:555–561, 1993. 117. Cohen JL, Jao JY: Enzymatic basis of cyclophosphamide activation
97. Danesi R, Fogli S, Gennari A, et al.: Pharmacokinetic- by hepatic microsomes of the rat, J Pharmacol Exp Ther 174:206–
pharmacodynamic relationships of the anthracycline anticancer 210, 1970.
drugs, Clin Pharmacokinet 41:431–444, 2002. 118. Colvin M, Brundrett RB, Kan MN, et al.: Alkylating properties of
98. Arrington KA, Legendre AM, Tabeling GS, et al.: Comparison phosphoramide mustard, Cancer Res 36:1121–1126, 1976.
of body surface area-based and weight-based dosage protocols for 119. Warry E, Hansen RJ, Gustafson DL, et al.: Pharmacokinetics of
doxorubicin administration in dogs, Am J Vet Res 55:1587–1592, cyclophosphamide after oral and intravenous administration to
1994. dogs with lymphoma, J Vet Intern Med 25:903–908, 2011.
99. Veterinary co-operative oncology group – common terminology 120. Stroda KA, Murphy JD, Hansen RJ, et al.: Pharmacokinetics of
criteria for adverse events (VCOG-CTCAE) following chemother- cyclophosphamide and 4-hydroxycyclophosphamide in cats after
apy or biological antineoplastic therapy in dogs and cats v1.0, Vet oral, intravenous, and intraperitoneal administration of cyclophos-
Comp Oncol 2:195–213, 2004. phamide, Am J Vet Res 78:862–866, 2017.
100. Bailey DB, Rassnick KM, Kristal O, et al.: Phase I dose escalation 121. Fetting JH, McCarthy LE, Borison HL, et al.: Vomiting induced
of single-agent vinblastine in dogs, J Vet Intern Med 22:1397–1402, by cyclophosphamide and phosphoramide mustard in cats, Cancer
2008. Treat Rep 66:1625–1629, 1982.
101. Vaughan A, Johnson JL, Williams LE: Impact of chemotherapeutic 122. Cox PJ: Cyclophosphamide cystitis—identification of acrolein as
dose intensity and hematologic toxicity on first remission duration the causative agent, Biochem Pharmacol 28:2045–2049, 1979.
in dogs with lymphoma treated with a chemoradiotherapy proto- 123. Charney SC, Bergman PJ, Hohenhaus AE, et al.: Risk factors for
col, J Vet Intern Med 21:1332–1339, 2007. sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclo-
102. Eschalier A, Lavarenne J, Burtin C, et al.: Study of histamine release phosphamide with or without concurrent administration of furose-
induced by acute administration of antitumor agents in dogs, Can- mide: 216 cases (1990–1996), J Am Vet Med Assoc 222:1388–1393,
cer Chemother Pharmacol 21:246–250, 1988. 2003.
103. Poirier VJ, Hershey AE, Burgess KE, et al.: Efficacy and toxicity 124. Peterson JL, Couto CG, Hammer AS, et al.: Acute sterile hemor-
of paclitaxel (taxol) for the treatment of canine malignant tumors, rhagic cystitis after a single intravenous administration of cyclo-
J Vet Intern Med 18:219–222, 2004. phosphamide in three dogs, J Am Vet Med Assoc 201:1572–1574,
104. von Euler H, Akerlund-Denneberg N, Rivera P, et al.: Efficacy and 1992.
safety in an open label single arm multi center phase III trial of a 125. Chan CM, Frimberger AE, Moore AS: Incidence of sterile hemor-
new formulation of paclitaxel (Paccal vet) in dogs with mast cell rhagic cystitis in tumor-bearing dogs concurrently treated with oral
®
tumours grade II and III, ESVONC Annual Congress, 2009. metronomic cyclophosphamide chemotherapy and furosemide: 55
105. Goodman LS, Wintrobe MM, et al.: Nitrogen mustard therapy; cases (2009–2015), J Am Vet Med Assoc 249:1408–1414, 2016.
use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris 126. Matsuyama A, Woods JP, Mutsaers AJ: Evaluation of toxicity of
(beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lym- a chronic alternate day metronomic cyclophosphamide chemo-
phosarcoma, leukemia and certain allied and miscellaneous disor- therapy protocol in dogs with naturally occurring cancer, Can Vet J
ders, J Am Med Assoc 132:126–132, 1946. 58:51–55, 2017.
106. Jacobson LO, Spurr CL, et al.: Studies on the effect of methyl bis 127. Laing EJ, Miller CW, Cochrane SM: Treatment of cyclophospha-
(beta-chloroethyl) amine hydrochloride on diseases of the hemo- mide-induced hemorrhagic cystitis in five dogs, J Am Vet Med Assoc
poietic system, J Clin Invest 25:909, 1946. 193:233–236, 1988.
107. Rhoads CP: Nitrogen mustards in the treatment of neoplastic dis- 128. Weller RE: Intravesical instillation of dilute formalin for treatment
ease; official statement, J Am Med Assoc 131:656–658, 1946. of cyclophosphamide-induced hemorrhagic cystitis in two dogs,
108. Kohn KW, Spears CL, Doty P: Inter-strand crosslinking of DNA J Am Vet Med Assoc 172:1206–1209, 1978.
by nitrogen mustard, J Mol Biol 19:266–288, 1966. 129. Frimberger AE, Moore AS, Rassnick KM, et al.: A combination
109. Skipper HE, Bennett LL, Langham WH: Over-all tracer studies chemotherapy protocol with dose intensification and autologous
with C labeled nitrogen mustard in normal and leukemic mice, bone marrow transplant (VELCAP-HDC) for canine lymphoma,
14
Cancer 4:1025–1027, 1951. J Vet Intern Med 20:355–364, 2006.
110. Goldenberg GJ, Vanstone CL, Israels LG, et al.: Evidence for a trans- 130. Warry EE, Willcox JL, Suter SE: Autologous peripheral blood
port carrier of nitrogen mustard in nitrogen mustard-sensitive and hematopoietic cell transplantation in dogs with T-cell lymphoma,
-resistant l5178y lymphoblasts, Cancer Res 30:2285–2291, 1970. J Vet Intern Med 28:529–537, 2014.
111. Rassnick KM, Mauldin GE, Al-Sarraf R, et al.: MOPP chemo- 131. Willcox JL, Pruitt A, Suter SE: Autologous peripheral blood hema-
therapy for treatment of resistant lymphoma in dogs: a retrospective topoietic cell transplantation in dogs with B-cell lymphoma, J Vet
study of 117 cases (1989–2000), J Vet Intern Med 16:576–580, 2002. Intern Med 26:1155–1163, 2012.